Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...